Table 2 Efficacy analysis (intension-to-treat population)

From: Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study

Endpoints

Group

No.of patients

No. of patients with events

Stratified Hazard ratio

Cox regression

Stratified

90%CI

log-rank test

DFS

     

p = 0.0549

 

6M group

654

226

 
 

12M group

650

208

0.858

0.732–1.004

 

RFS

p = 0.0143

 

6M group

654

199

 
 

12M group

650

169

0.796

0.670–0.945

 

OS

     

p = 0.0124

 

6M group

654

113

 
 

12M group

650

87

0.727

0.575–0.919

 
  1. DFS disease-free survival, RFS relapse-free survival, OS overall survival